Thermo Fisher's $244 Million Plant-Sale Loss Nearly Wipes Out Its $72 Million Microbiology Gain
A held-for-sale loss on a drug-manufacturing site offset the microbiology sale gain as 2026 severance actions reached about 2% of staff.
Thermo Fisher Scientific booked a $244 million held-for-sale loss in the third quarter on a deal to sell a pharma services manufacturing plant, a hit that outweighs the $72 million pre-tax gain from selling its microbiology business, according to its 10-Q filed Friday. The company, which supplies lab instruments, reagents, diagnostics and outsourced drug development services, also said severance actions this year now touch about 2% of its workforce.
Two divestitures, opposite results
On September 4, the company agreed to sell a pharma services manufacturing facility, along with its customer contracts and employees, out of the Laboratory Products and Biopharma Services segment. It took the $244 million loss in the quarter.
Astorg bought the microbiology unit on August 12 for roughly $1.07 billion, paid partly in cash and partly via a promissory note, producing a $72 million pre-tax gain. The business sat in Specialty Diagnostics, whose third-quarter revenue slid to $1,098 million from $1,174 million a year earlier. The second-quarter report had carried the microbiology sale as pending, with a $60 million impairment as the main charge.
Third-quarter restructuring and other costs totaled $199 million. Laboratory Products and Biopharma Services bore $256 million, while Specialty Diagnostics showed a $(60) million credit from the gain.
Layoffs widen, charges shrink
Severance actions tied to facility consolidations and cost cuts affected about 2% of the workforce in 2026, against about 1% in the second-quarter filing. The company has identified further actions, mostly in Laboratory Products and Biopharma Services, that it expects will cost about $180 million, primarily in 2026, down from about $220 million at the prior report. It expects to identify more actions in future periods.
The broader quarter was solid. Revenue grew 9% to $12,137 million, and GAAP operating income rose 17% to $2,263 million, according to the earnings release issued October 21. Adjusted operating income, which excludes the sale gain and the loss, rose 15% to $2,968 million.
Debt-funded growth and a December maturity
Cash and equivalents fell to $5.46 billion from $9.85 billion at the start of the year, and total debt rose to $41.37 billion from $39.38 billion. Net interest expense climbed to $165 million in the quarter from $113 million, which the 10-Q attributes to added debt funding buybacks, dividends and the Clario purchase.
In the first nine months the company repurchased $4.00 billion of stock, and $1.00 billion remains under its authorization. A $1.00 billion senior note, carrying a 5.00% coupon, is due December 5, 2026. Remaining performance obligations on open customer contracts stood at $29.87 billion at September 26, about 52% of which the company expects to recognize within twelve months.
The $1.00 billion note due December 5 is the next hard date on the company's debt schedule.
Sources
- 10-Q Filing — Thermo Fisher Scientific (TMO) — SEC EDGAR
- 10-Q Filing — Thermo Fisher Scientific (TMO), Q2 FY2026 filed 2026-07-31 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, q32026earnings8kex99_1.htm) — Thermo Fisher Scientific, filed 2026-10-21 — SEC EDGAR
- Is Thermo Fisher Scientific (TMO) Fully Priced On Its Latest Results? — Yahoo Finance
- Thermo Fisher Scientific Inc (TMO) Stock Forecasts — Yahoo Finance
- Thermo Fisher Scientific (TMO) Lands Spotlight In Fast Growing Cell And Gene Therapy CRO Market — Yahoo Finance
- Thermo Fisher (TMO) Stock Could Trade At A Premium On Strong Q3 Results — Yahoo Finance
- Analyst Observations | Nasdaq Dorsey Wright — dorseywright.nasdaq.com